MediciNova, Inc.

$1.39+0.72%(+$0.01)
TickerSpark Score
41/100
Weak
44
Valuation
25
Profitability
20
Growth
84
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNOV research report →

52-Week Range28% of range
Low $1.17
Current $1.39
High $1.96

Companywww.medicinova.com

MediciNova, Inc. , a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.

CEO
Yuichi Iwaki
IPO
2006
Employees
13
HQ
La Jolla, CA, US

Price Chart

+1.46% · this period
$1.88$1.53$1.18May 20Nov 18May 20

Valuation

Market Cap
$68.42M
P/E
-5.84
P/S
114.67
P/B
0.00
EV/EBITDA
2146.67
Div Yield
0.00%

Profitability

Gross Margin
15.20%
Op Margin
-2164.84%
Net Margin
-1964.35%
ROE
-0.12%
ROIC
-0.03%

Growth & Income

Revenue
$409.66K · 0.00%
Net Income
$-11,997,957 · -8.58%
EPS
$-0.24 · -4.35%
Op Income
$-13,283,000
FCF YoY
7.83%

Performance & Tape

52W High
$1.96
52W Low
$1.17
50D MA
$1.41
200D MA
$1.41
Beta
0.63
Avg Volume
45.15K

Get TickerSpark's AI analysis on MNOV

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jan 16, 26Matsuda Kazukoother350,000
Jan 16, 26IWAKI YUICHIother450,000
Jun 17, 25Nagao Hidekiother20,000
Jun 17, 25Lemerond Nicoleother20,000
Jun 17, 25BEAVER CAROLYNother20,000
Feb 12, 25Nagao Hidekiother24,500
Feb 12, 25Matsuda Kazukoother100,000
Feb 12, 25Lemerond Nicoleother24,500
Feb 12, 25IWAKI YUICHIother100,000
Feb 12, 25BEAVER CAROLYNother24,500

Our MNOV Coverage

We haven't published any research on MNOV yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate MNOV Report →

Similar Companies